Approved for: NSCLC
Biomarker: test

Bevacizumab (Avastin/Mvasi/Zirabev) approved Chemotherapy for Nonsquamous non-small cell lung cancer (NSCLC) that is locally advanced, cannot be removed by surgery, has metastasized, or has recurred. It is used with carboplatin and paclitaxel as first-line therapy. This use is approved for the Avastin, Zirabev, and Mvasi brands of bevacizumab.